Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement

Fineline Cube Jun 17, 2026
Company Deals

Servier Group Partners with n-Lorem Foundation to Develop ASO Therapies for Rare Neurodevelopmental Disorders

Fineline Cube Jun 17, 2026
Company Deals

Shanghai Juncell Therapeutics Files for HKEX Listing with Breakthrough TIL Therapy GC101 for Solid Tumors

Fineline Cube Jun 17, 2026
Company Deals

Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets

Fineline Cube Jun 16, 2026
Company Deals

Harbour BioMed and BioMap Launch MegaStream TechBio – Next-Generation AI Drug Discovery Company Targeting Global Markets

Fineline Cube Jun 16, 2026
Policy / Regulatory

NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines’ Brukinsa (zanubrutinib)

Fineline Cube Jun 17, 2026
Company Drug

Walvax Biotechnology’s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial

Fineline Cube Jun 17, 2026
Company Drug

Insilico Medicine’s NLRP3 Inhibitor ISM8969 Achieves First-in-Human Milestone in Phase I Trial for CNS Disorders

Fineline Cube Jun 17, 2026
Company Drug

NeoCura Bio-Medical Gains NMPA Approval for mRNA Cancer Vaccine Trial

Fineline Cube Jun 9, 2025

China-based NeoCura Bio-Medical Technology Co., Ltd. announced that it has received approval from the National...

Company Drug

YolTech Receives FDA Clearance for PCSK9-Targeted Base Editing Drug YOLT-101

Fineline Cube Jun 9, 2025

Shanghai-based YolTech Therapeutics announced that it has received clearance from the US Food and Drug...

Company Deals

Kindstar Global Partners with Biostate AI to Advance Precision Medicine

Fineline Cube Jun 9, 2025

China-based Kindstar Global (HKG: 9960) announced the establishment of a joint venture (JV) with US-headquartered...

Company Medical Device

Genesis MedTech Wins NMPA Approval for Locally Developed Thrombus Aspiration Catheter

Fineline Cube Jun 9, 2025

Singapore-based Genesis MedTech announced that it has received marketing approval from China’s National Medical Products...

Company Deals

Zelgen Bio Collaborates with Merck KGaA for rhTSH Promotion in China

Fineline Cube Jun 6, 2025

China’s Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced a collaboration agreement with Merck KGaA...

Company Drug

HELP Therapeutics’ iPSC-Derived Cardiomyocyte Therapy Enters US Clinical Trials

Fineline Cube Jun 6, 2025

Nanjing-based HELP Therapeutics Co. Ltd, a clinical-stage cell therapy company, announced that its innovative induced...

Company Deals

Lancet Robotics Secures Series A+ Funding for Surgical Robot Development

Fineline Cube Jun 6, 2025

Shenzhen-based Lancet Robotics, a developer of orthopedic joint replacement surgical robots, has reportedly secured “tens...

Legal / IP

Biocytogen’s RenMab Platform Wins Japanese Patent, Expanding IP Portfolio

Fineline Cube Jun 6, 2025

China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced that its RenMab platform, a key...

Company Deals Drug

Bayer’s Vividion Gains Global Rights to WRN Inhibitor VVD-214

Fineline Cube Jun 6, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) announced that its wholly owned subsidiary Vividion Therapeutics,...

Company Deals

Nanjing Leads Biolabs Files for Hong Kong IPO Amid Product Pipeline Progress

Fineline Cube Jun 6, 2025

China-based Nanjing Leads Biolabs Co., Ltd., a clinical-stage biotech company focusing on oncology and autoimmune...

Company Medical Device

Acotec Scientific Gains NMPA Approval for AcoArt Verbena Vertebral Balloon

Fineline Cube Jun 6, 2025

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has received marketing approval from China’s National Medical...

Company Drug

Hengrui Pharmaceuticals Gains NMPA Approval for Phase Ib/II Study of SHR-A1811, Adebrelimab and Famitinib in Solid Tumors

Fineline Cube Jun 6, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received approval from...

Company Deals

Qure Biotechnology Secures RMB 100 Million Series C1 Financing

Fineline Cube Jun 6, 2025

China-based Qure Biotechnology (Shanghai) Co., Ltd. announced the completion of a Series C1 financing round...

Company Drug

Lianhuan Pharma Gains NMPA Approval for No-Spa Generic

Fineline Cube Jun 6, 2025

China-based Jiangsu Lianhuan Pharmaceutical Co., Ltd (SHA: 600513) announced that it has received market clearance...

Company Drug

Roche’s Evrysdi 5mg Tablet Gains EU Commission Approval for Spinal Muscular Atrophy

Fineline Cube Jun 6, 2025

Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced that the European Commission (EC) has...

Company Deals

Shanghai OPM Biosciences Plans Acqusition of PharmaLegacy Labs for RMB 1.45 Billion

Fineline Cube Jun 6, 2025

Shanghai OPM Biosciences Co., Ltd (SHA: 688293), a China-based cell culture-focused Contract Development and Manufacturing...

Company Drug

Sunshine Guojian’s SSGJ-613 Meets Phase III Endpoints in Acute Gouty Arthritis

Fineline Cube Jun 6, 2025

China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), announced...

Policy / Regulatory

NHSA Strengthens Pharmaceutical Pricing and Procurement Credit Evaluation Mechanism

Fineline Cube Jun 6, 2025

The National Healthcare Security Administration (NHSA) issued a notification this week to refine its credit...

Policy / Regulatory

China Issues Whistleblower Incentives for Drug and Medical Device Safety Violations

Fineline Cube Jun 6, 2025

China’s National Medical Products Administration (NMPA), Ministry of Finance (MoF), and State Administration for Market...

Policy / Regulatory

China’s National Health Commission Mandates Labor Pain Management Services Expansion

Fineline Cube Jun 6, 2025

China’s National Health Commission (NHC) issued a notification mandating the comprehensive promotion of labor pain...

Posts pagination

1 … 167 168 169 … 685

Recent updates

  • Walvax Biotechnology’s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial
  • Insilico Medicine’s NLRP3 Inhibitor ISM8969 Achieves First-in-Human Milestone in Phase I Trial for CNS Disorders
  • Hengrui Pharmaceuticals Expands Dalpiciclib Label with NMPA Approval for Early Breast Cancer Adjuvant Therapy
  • WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement
  • Hengrui Pharmaceuticals Receives NMPA Clinical Approvals for Two Novel Anti-Tumor Candidates SHR-6914 and HRS-7525, Addressing Unmet Needs in Prostate Cancer and Solid Tumors
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Walvax Biotechnology’s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial

Company Drug

Insilico Medicine’s NLRP3 Inhibitor ISM8969 Achieves First-in-Human Milestone in Phase I Trial for CNS Disorders

Company Drug

Hengrui Pharmaceuticals Expands Dalpiciclib Label with NMPA Approval for Early Breast Cancer Adjuvant Therapy

Company Deals

WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.